Given the growing body of evidence suggesting a role for RET in endocrine resistance and estrogen-independent outgrowth, but uncertain function in primary breast cancers, further examination of gains in RET expression in luminal breast tumors during local recurrence or metastasis may prove to be a critical step in advancing of care for endocrine-refractory disease. The gene discussed is RET; the disease is breast cancer.